Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SXC-2023 in Adults With Moderate to Severe Trichotillomania
NCT03797521Phase 2Completed
- Sponsor
- Promentis Pharmaceuticals, Inc.
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SXC-2023 in trichotillomania (TTM) (4 arms), sponsored by Promentis Pharmaceuticals, Inc. Primary endpoint: Treatment-Emergent Adverse Events up to 7 weeks. Started Dec 2018; status: completed.
02
Drugs
SXC-2023
03
Conditions
trichotillomania (TTM)
Beyond the preview
Go deeper on NCT03797521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797521.